Table 1 Mortality rates by sociodemographic and clinical characteristics at enrolment into HIV services for PLHIV patients in three regions of Northern Tanzania (N = 88,934)
From: Effect of tuberculosis infection on mortality of HIV-infected patients in Northern Tanzania
Number of PLHIV (%) | Number of deaths for all PLHIV (%) | Person-years of follow-up (in 1000 years) | Mortality rate per 1000 for PLHIV (95% CI) | |
|---|---|---|---|---|
Characteristics | 88,934 | 4,757 (5.3) | 167.7 | 28.4 (27.6–29.2) |
Age (N = 86,050) | ||||
• 15–24 • 25–34 • 35–44 • 45–55 • Above 55 | 8070 (9.4) 23,648 (27.5) 29,007 (33.7) 16,906 (19.6) 8419 (9.8) | 258 (3.2) 853 (3.6) 1600 (5.5) 1147 (6.8) 899 (10.7) | 10.25 31.99 59.71 42.46 23.29 | 25.2 (22.3–28.4) 26.7 (24.9–28.5) 26.8 (25.5–28.1) 27.0 (25.5–28.6) 38.6 (36.2–41.2) |
Sex (N = 88,934) | ||||
• Male • Female | 25,618 (29.1) 63,316 (70.9) | 1906 (7.4) 2851 (4.5) | 45.23 122.46 | 42.1 (40.3–44.1) 23.3 (22.4–24.2) |
Marital status (N = 82,241) | ||||
• Cohabiting • Divorced • Married • Single • Widow/widower | 1161 (1.4) 8067 (9.8) 43,603 (53.0) 23,298 (28.3) 6112 (7.4) | 51 (4.4) 530 (6.6) 2204 (5.1) 1345 (5.8) 410 (6.7) | 2.23 16.99 85.50 41.99 13.36 | 22.9 (17.4–30.1) 31.2 (28.7–34.0) 25.8 (24.7–26.9) 32.0 (30.4–33.8) 30.7 (27.9–33.8) |
Region (N = 88,934) | ||||
• Arusha • Kilimanjaro • Tanga | 14,316 (16.1) 29,524 (33.2) 45,094 (50.7) | 517 (3.6) 1293 (4.4) 2947 (6.5) | 16.21 54.02 97.47 | 31.9 (29.3–34.8) 23.9 (22.7–25.3) 30.2 (29.2–31.3) |
TB status (N = 88,934) | ||||
• No TB • TB co-infection | 83,488 (93.9) 5446 (6.1) | 4086 (4.9) 671 (1.2) | 156.08 11.61 | 26.2 (25.4–27.0) 57.8 (53.6–62.3) |
Body weight (N = 83,378) | ||||
• Below 40 kg • 40–60 kg • Above 60 kg | 7,993 (9.6) 49,815 (59.7) 25,570 (30.7) | 691 (8.6) 3014 (6.1) 790 (3.1) | 10.90 97.19 51.15 | 63.4 (58.9–68.3) 31.0 (29.9–32.1) 15.4 (14.4–16.6) |
HIV WHO stage (N = 86,460) | ||||
• Stage 1 • Stage 2 • Stage 3 • Stage 4 | 22,238 (25.7) 19,914 (23.0) 32,348 (37.4) 11,960 (13.8) | 482 (2.2) 940 (4.7) 2091 (6.5) 1159 (9.7) | 29.82 38.35 70.83 25.55 | 16.2 (14.8–17.7) 24.5 (23.0–26.1) 29.5 (28.3–30.8) 45.4 (42.8–48.0) |
CD4 categories (N = 28,013) | ||||
• Below 350 • 350-500 • Above 500 | 17,835 (63.7) 4756 (17.0) 5422 (19.4) | 1479 (8.3) 157 (3.3) 100 (1.8) | 34.19 8.71 7.87 | 43.3 (41.1–45.5) 18.0 (15.4–21.1) 12.7 (10.4–15.5) |
Functional status (N = 88,283) | ||||
• Bedridden • Ambulatory • Working | 4199 (4.8) 590 (0.7) 83,494 (94.6) | 503 (12.0) 78 (13.2) 4152 (5.0) | 7.14 0.58 159.02 | 79.5 (64.6–76.9) 135.6 (108.6–169.3) 26.1 (25.3–26.9) |
Nutritional status (N = 68,864) | ||||
• Ok • Moderate • Severe | 63,626 (92.4) 4843 (7.0) 395 (0.6) | 3237 (5.1) 511 (10.6) 53 (13.4) | 113.89 8.44 0.42 | 28.4 (27.5–29.4) 60.6 (55.5–66.1) 125.6 (95.9–164.3) |
ARV adherence (N = 46,438) | ||||
• Good adherence • Poor adherence | 45,281 (97.5) 1157 (2.5) | 2403 (5.3) 127 (11.0) | 109.7 2.7 | 21.9 (21.0–22.8) 46.6 (39.2–55.5) |
ARV regimen (N = 51,525) | ||||
• First line • Second line | 50,314 (97.6) 1211 (2.4) | 2669 (5.3) 73 (6.0) | 111.0 3.21 | 24.0 (23.2–25.0) 22.7 (18.1–28.6) |